Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals

Hepatitis C is a global public health burden. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. Introduction of different direct acting antivirals targeting the hepatitis C proteins has considerably increased rates of sustained viral response. First active s...

Full description

Saved in:
Bibliographic Details
Published in:Journal of comparative effectiveness research 2015-05, Vol.4 (3), p.267-277
Main Authors: Stahmeyer, Jona T, Rossol, Siegbert, Krauth, Christian
Format: Article
Language:English
Subjects:
Analysis
Antiviral agents
chronic hepatitis C
cost-effectiveness
costs
direct acting antivirals
Dosage and administration
Drug therapy
Economic aspects
effectiveness
Health care costs
Hepatitis C
treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis C is a global public health burden. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. Introduction of different direct acting antivirals targeting the hepatitis C proteins has considerably increased rates of sustained viral response. First active substances introduced in 2011 were NS3/4A protease inhibitors telaprevir and boceprevir. In 2013/2014 the second generation of direct acting antivirals sofosbuvir, simeprevir, daclatasvir, ledipasvir and 3D therapy containing ombitasvir/paritaprevir/ritonavir and dasabuvir followed. This review focuses on treatment outcomes and costs of introduced direct acting antivirals. We provide an overview on SVR-rates in clinical trials and clinical practice, treatment costs in different countries as well as results of cost-effectiveness analyses for different treatment strategies.
ISSN:2042-6305
2042-6313
DOI:10.2217/cer.15.13